Track Lucid Diagnostics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Lucid Diagnostics Inc. Common Stock LUCD · Stock Open Lucid Diagnostics Inc. Common Stock in new tab

0.7345 USD
EPS
-1.26
ROE
-255.60
Beta
1.49
Target Price
3.83 USD
Loading chart...
Key Metrics
Earnings dateMarch 25, 2027
EPS-1.26
Book Value-0.69
Debt/Equity119.20
% Insiders67.612%
Growth
Revenue Growth1.24%
Estimates
Forward P/E-1.25
Forward EPS-0.73
Target Mean Price3.83

DCF valuation

Model fair value for Lucid Diagnostics Inc. Common Stock (LUCD)
Result
Sign in to run the valuation for LUCD.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 3.83 USD (low 2.50, high 8.00)
Low 2.50
Mean 3.83
High 8.00
Price 0.7345
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Lucid Diagnostics Inc. Common Stock Logo Lucid Diagnostics Inc. Common Stock Analysis (LUCD)

United States Health Care Official Website Stock

Is Lucid Diagnostics Inc. Common Stock a good investment? Lucid Diagnostics Inc. Common Stock (LUCD) is currently trading at 0.7345 USD. Market analysts have a consensus price target of 3.83 USD. This suggests a potential upside from current levels.

Earnings Schedule: Lucid Diagnostics Inc. Common Stock is expected to release its next earnings report on March 25, 2027. The market consensus estimate for Forward EPS is -0.73.

Investor FAQ

Does Lucid Diagnostics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Lucid Diagnostics Inc. Common Stock?

Lucid Diagnostics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 25, 2027. The company currently has a trailing EPS of -1.26.

Company Profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Exchange Ticker
NMS (United States) LUCD
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion